Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity (2021 - 2025)

Historic Common Equity for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $11.6 million.

  • InMed Pharmaceuticals' Common Equity rose 3805.85% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 3805.85%. This contributed to the annual value of $13.4 million for FY2025, which is 4593.02% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Common Equity is $11.6 million, which was up 3805.85% from $13.4 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Common Equity's 5-year high stood at $15.2 million during Q3 2021, with a 5-year trough of -$9.6 million in Q3 2023.
  • For the 5-year period, InMed Pharmaceuticals' Common Equity averaged around $10.0 million, with its median value being $11.1 million (2024).
  • Per our database at Business Quant, InMed Pharmaceuticals' Common Equity tumbled by 18701.07% in 2023 and then surged by 18765.26% in 2024.
  • InMed Pharmaceuticals' Common Equity (Quarter) stood at $14.2 million in 2021, then increased by 1.18% to $14.3 million in 2022, then decreased by 10.9% to $12.8 million in 2023, then crashed by 51.6% to $6.2 million in 2024, then surged by 87.49% to $11.6 million in 2025.
  • Its Common Equity was $11.6 million in Q3 2025, compared to $13.4 million in Q2 2025 and $7.0 million in Q1 2025.